Patients should not donate blood or blood products while receiving sonidegib and for at least 20 months after the last dose.
- TRADE NAME: Odomzo (Novartis)
- INDICATIONS: Basal cell carcinoma
- CLASS: Hedgehog (Hh) signaling pathway inhibitor
- HALF-LIFE: 28 days
- FDA APPROVAL DATE: 07/24/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atazanavir, Carbamazepine, Diltiazem, Efavirenz, Fluconazole, Itraconazole, Ketoconazole, Modafinil, Nefazodone, Phenobarbital, Phenytoin, Posaconazole, Rifabutin, Rifampin, Saquinavir, St John's Wort, Telithromycin, Voriconazole - PREGNANCY: Can cause fetal harm
- See adverse reactions attributed to class:
EMBRYO-FETAL TOXICITY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of sonidegib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
